| 1 |
Cheng A, Lang J. Survival analysis of lymph node resection in ovarian cancer: a population-based study[J]. Front Oncol, 2020, 10：355.
|
| 2 |
Maggioni A, Benedetti Panici P, Dell′Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis[J]. Br J Cancer, 2006, 95(6)：699-704.
|
| 3 |
Ercelep O, Ozcelik M, Gumus M. Association of lymphadenectomy and survival in epithelial ovarian cancer[J]. Curr Probl Cancer, 2019, 43(2)：151-159.
|
| 4 |
Eoh KJ, Lee JY, Yoon JW, et al. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery[J]. Oncotarget, 2017, 8(23)：37807-37816.
|
| 5 |
Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial[J]. J Natl Cancer Inst, 2005, 97(8)：560-566.
|
| 6 |
du Bois A, Reuss A, Harter P, et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase Ⅲ multicenter trials[J]. J Clin Oncol, 2010, 28(10)：1733-1739.
|
| 7 |
Harter P., Sehouli J., Lorusso D., et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms[J]．N Engl J Med, 2019, 380(9)：822-832.
|
| 8 |
Zhou J, Zhang WW, Zhang QH, et al. The effect of lymyphadenectomy in advanced ovarian cancer according to residual tumor status：a population-based study[J]．Int J Surg, 2018, 52(4)：11-15.
|
| 9 |
Rungruang BJ, Miller A, Krivak TC，et al. What is the role of retroperitoneal exploration in optimally debulked stage ⅢC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study[J]. Cancer, 2017, 123(6)：985-993.
|
| 10 |
Rungruang BJ, Miller A, Krivak TC, et al. What is the role of retroperitoneal exploration in optimally debulked stage ⅢC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study[J]. Cancer, 2017, 123(6)：985-993.
|
| 11 |
Bogani G, Leone Roberti Maggiore U, Chiappa V, et al. The addition of lymphadenectomy to secondary cytoreductive surgery in comparison with bulky node resection in patients with recurrent ovarian cancer[J]. Int J Gynaecol Obstet, 2018, 143(3)：319-324.
|
| 12 |
Cosin JA, Fowler JM, Chen MD, et al. Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking[J]. Cancer, 1998, 82(11)：2241-2248.
|
| 13 |
Pieterse QD, Kenter GG, Gaarenstroom KN, et al. The number of pelvic lymph nodes in the quality control and prognosis of radical hysterectomy for the treatment of cervical cancer[J]. Eur J Surg Oncol, 2007, 33(2)：216-221.
|
| 14 |
Cibula D, Dostalek L, Hillemanns P, et al. Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study[J]. Eur J Cancer, 2021, 143：88-100.
|
| 15 |
Altgassen C, Hertel H, Brandstädt A, et al. Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group[J]. J Clin Oncol, 2008, 26(18)：2943-2951.
|
| 16 |
Wydra D, Sawicki S, Wojtylak S, et al. Sentinel node identification in cervical cancer patients undergoing transperitoneal radical hysterectomy: a study of 100 cases[J]. Int J Gynecol Cancer, 2006, 16(2)：649-654.
|
| 17 |
Katsoulakis E, Mattes MD, Rineer JM, et al. Contemporary analysis of pelvic and para-aortic metastasis in endometrial cancer using the SEER registry[J]. Int J Gynaecol Obstet, 2014, 127(3)：293-296.
|
| 18 |
Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial[J]. J Natl Cancer Inst, 2008, 100(23)：1707-1716.
|
| 19 |
ASTEC study group, Kitchener H, Swart AM, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study[J]. Lancet, 2009, 373(9658)：125-136.
|
| 20 |
Zahl Eriksson AG, Ducie J, Ali N, et al. Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion[J]. Gynecol Oncol, 2016, 140(3)：394-399.
|
| 21 |
Abe R, Taneichi N. Lymphatic metastasis in experimental cecal cancer. Effectiveness of lymph nodes as barriers to the spread of tumor cells[J]. Arch Surg, 1972, 104(1)：95-98.
|
| 22 |
Maglioco A, Machuca D, Mundiñano J, et al. Lymphadenectomy exacerbates tumor growth while lymphadenectomy plus the adoptive transfer of autologous cytotoxic cells and low-dose cyclophosphamide induces regression of an established murine fibrosarcoma[J]. Cancer Immunol Immunother, 2011, 60(3)：389-399.
|
| 23 |
Vermeulen PB, Colpaert C, Salgado R, et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia[J]. J Pathol, 2001, 195(3)：336-342.
|
| 24 |
Yost KE, Satpathy AT, Wells DK, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade[J]. Nat Med, 2019, 25(8)：1251-1259.
|
| 25 |
Schenkel JM, Herbst RH, Canner D, et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+CD8+T cells in tumor-draining lymph nodes[J]. Immunity, 2021, 54(10)：2338-2353.e6.
|
| 26 |
Huang Q, Wu X, Wang Z, et al. The primordial differentiation of tumor-specific memory CD8+T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes[J]. Cell, 2022, 185(22)：4049-4066.e25.
|
| 27 |
Rahim MK, Okholm TLH, Jones KB, et al. Dynamic CD8+T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes[J]. Cell, 2023, 186(6)：1127-1143.e18.
|